Anthropic’s Claude agents outperformed human researchers and produced “alien science,” raising new questions about AI ...

Meta's new hyperagent framework breaks the AI "maintenance wall," allowing systems to autonomously rewrite their own logic ...

Infosecurity outlines key recommendations for CISOs and security teams to implement safeguards for AI-assisted coding ...

Recursion has merged Exscientia’s AI-driven chemistry with its own phenomics and a new ClinTech real-world-data capability to streamline discovery and trials, consolidated R&D to five internal ...

OpenAI announced Thursday that it has entered into an agreement to acquire Astral, the company behind popular open source Python development tools such as uv, Ruff, and ty, and integrate the company ...

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor ...

A month has gone by since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have lost about 16.5% in that time frame, underperforming the S&P 500. Will the recent negative trend ...

A python’s extraordinary metabolism may unlock new paths to healthy weight loss and even fight age-related muscle loss. In less than a decade, new weight-loss drugs have transformed the market, ...

Stop piping grep into five other commands. It already handles most of that.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...